BNB Plus Corp. (BNBX) Receives Two New Orders for LineaDNA(TM) from Genetic Medicine Developers
MWN-AI** Summary
BNB Plus Corp. (Nasdaq: BNBX) has recently announced that its biopharmaceutical subsidiary, LineaRx, Inc., has secured two new orders for its LineaDNA™ product from prominent genetic medicine developers. The production and shipment of these orders are scheduled to be completed by June 2026. Clay Shorrock, President and CEO of BNBX, expressed satisfaction with the orders, highlighting the technical excellence of the LineaDNA platform and the company's operational readiness.
Additionally, BNBX provided an update on its financial performance and ongoing operational strategies. LineaRx's operational efficiency has led to an accelerated order of $1.2 million—marking the largest LineaDNA order in its history. The company anticipates shipping over $1.5 million of LineaDNA in the first half of 2026, with 8 grams of DNA expected to ship in the current quarter. Cost-saving initiatives have also been a focus for BNBX; streamlining operations has resulted in estimated annual savings of $3 million. The company's recent move to a smaller corporate headquarters is projected to yield an additional $600,000 in annual cost savings.
In terms of its digital asset portfolio, BNBX holds significant BNB tokens and OBNB trust units, valued at over $10.7 million as of late February 2026. This figure is more than double the company's current market capitalization. Overall, BNBX is optimistic about the future performance of its LineaRx subsidiary and anticipates strong financial improvements in the upcoming quarters. The company continues to leverage innovative strategies to enhance its position within the biopharmaceutical and blockchain sectors.
MWN-AI** Analysis
BNB Plus Corp. (BNBX) recently announced significant developments that underscore its upward potential, particularly in its biopharmaceutical subsidiary, LineaRx. The receipt of two new orders for its LineaDNA platform from reputable genetic medicine developers not only reinforces the technical prowess of its offerings but also highlights ongoing demand in a rapidly evolving industry. With production expected to be completed by June 2026, these contracts could assure BNBX steady revenue streams leading into 2026.
Financially, BNBX is positioning itself well for future growth. The recent $1.2 million accelerated order is a notable milestone, marking the largest in the company's history. This, alongside projected first-half revenues exceeding $1.5 million, bodes well for operational performance as the organization focuses on efficiency enhancements. The reported cost-saving strategies, including a move to a smaller headquarters that could save over $600,000 annually, suggest that management is adept at mitigating expenses—an essential factor for maintaining profitability in a cost-sensitive sector.
Furthermore, BNBX’s substantial holdings in BNB tokens, valued over $10.7 million, provide a promising digital asset portfolio that complements its biopharmaceutical operations. Given the volatility in cryptocurrency markets, this strategy can enhance liquidity and capitalize on bullish trends, especially if BNB’s price appreciates significantly from its current valuation of $598.
Investors should consider BNBX for exposure to the combined growth of genomic medicine and digital assets. However, potential investors must remain cognizant of the inherent risks associated with market volatility, regulatory nuances surrounding cryptocurrencies, and the biotech sector's competitive landscape. Overall, BNBX represents a balanced opportunity in high-growth industries with prudent management signaling operational strength.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Provides Updated on BNB Token Holdings and Operating Company Performance
BNB Plus Corp. (Nasdaq: BNBX) ("BNBX" or the "Company") today announced that its biopharmaceutical subsidiary, LineaRx, Inc. ("LineaRx"), has received two new orders for LineaDNA from well-established developers of genetic medicines. Production and shipment of both orders is expected to be completed prior to June 2026.
"We're pleased to receive these new orders from leading genetic medicine companies,” said Clay Shorrock, President and CEO of BNBX. “We believe our continued engagements with top-tier customers demonstrates both the technical excellence of our LineaDNA platform and our continued operational execution."
The Company also provided a brief corporate update.
Enterprise Value and Strong Operating Performance
LineaRx continues to demonstrate strong operational performance. The Company recently received a $1.2 million accelerated LineaDNA order , representing the largest LineaDNA order in its history. Inclusive of this recent order, LineaRx expects to ship over $1.5 million of LineaDNA to customers in the diagnostic and genetic medicines markets in the first half of calendar year 2026, with approximately 8 grams of DNA expected to ship in the current quarter.
The Company also continues to focus on enhancing operational efficiency and driving cost savings across its business operations. BNBX has implemented comprehensive cost reduction initiatives, streamlining operations and achieving approximately $3 million in estimated annual cost savings in the legacy LineaRx business. In addition, the Company recently completed its move into a new smaller corporate headquarters, resulting in expected additional annualized cost savings of over $600,000.
Building on cost optimization and manufacturing strength, the Company anticipates LineaRx will demonstrate strong financial improvement in FY26Q2 and beyond.
BNB Token Holdings and Digital Asset Portfolio
The Company maintains significant holdings of BNB tokens and OBNB trust units as part of its digital asset portfolio. At a current value of $598 per token, the Company’s BNB treasury stands at more than $10.7 million as of February 23, 2026, more than double BNBX’s current market cap.
About BNB Plus Corp.
BNB Plus unlocks streamlined access to the Binance ecosystem, delivering non-directional yield strategies and long BNB exposure, powering the future of blockchain through a transparent, actively managed BNB treasury. The Company’s differentiated strategy blends sophisticated DeFi yield generation with Binance-native opportunities, unlocking access to high-performance digital assets for investors traditionally excluded from the space. Formerly Applied DNA Sciences, Inc., BNB Plus continues to commercialize the Company’s proprietary nucleic acid production solutions for the biopharmaceutical and diagnostics markets.
About LineaDNA™
LineaDNA is LineaRx's proprietary cell-free DNA production platform offering a superior alternative to conventional plasmid-based methods. Leveraging the company's expertise in large-scale PCR, LineaDNA produces high-fidelity DNA free of adventitious sequences with rapid scalability and chemical modification compatibility. The platform generates DNA constructs from 100 base pairs to 20 kilobases in quantities from milligrams to grams under RUO, GLP, and GMP quality standards, serving genetic medicine and diagnostic markets.
Forward Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “believe,” “continues,” “estimate,” “expect,” “potential,” “may,” “will,” “project,” and other words of similar meaning. Forward-looking statements are statements other than historical facts and address various matters including, without limitation, statements relating to future financial and operating condition and performance, anticipated cost savings, the anticipated ability to produce and ship LineaDNA deliveries, the future operating performance of the Company's LineaRx subsidiary and/or the LineaDNA platform, and other projections or statements of plans and objectives.
These forward-looking statements are based on current expectations, estimates, assumptions, and projections, and involve known and unknown risks, uncertainties, and other factors—many of which are beyond the Company’s control—that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, failure to realize the anticipated benefits of the proposed digital asset treasury strategy; changes in business, market, financial, political and regulatory conditions, risks relating to the Company’s operations and business, including the highly volatile nature of the price of BNB and other cryptocurrencies, the illiquidity of the OBNB trust units owned by the Company, risks related to the Company’s ability to raise and deploy capital effectively, risks relating to an unproven yield generation strategy, the risk that the price of the Company’s common stock may be highly correlated to the price of the digital assets that it holds, risks related to increased competition in the industries in which the Company does and will operate, risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally, risks relating to the treatment of crypto assets for U.S. and foreign tax purposes, risks related to the unknown returns, liquidity and/or token accumulation that the Company’s BNB treasury strategy will generate, risks relating to market volatility, cybersecurity and custody of digital assets, potential changes in laws or accounting standards relating to cryptocurrency, and regulatory developments affecting BNB or other digital assets, the unknown future customer demand for DNA produced by its LineaRx subsidiary and/or its LineaDNA platform, the unknown future amount of revenues and profits that will result from its LineaRx subsidiary and/or its LineaDNA platform, as well as those risks and uncertainties identified in the Company’s filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements.
Visit www.BNB.plus for more information. Follow us on X and LinkedIn. Join our mailing list.
Web: www.BNB.plus
X: BNBX_Corp
View source version on businesswire.com: https://www.businesswire.com/news/home/20260224243091/en/
Investor Relations contact: John Ragozzino Jr., CFA BnB@icrinc.com
FAQ**
How does the operational performance of BNB Plus Corp. (formerly Applied DNA Sciences Inc. BNBX) position it in the competitive landscape of genetic medicine and digital asset markets?
What specific measures are being implemented to mitigate risks associated with BNBX's significant BNB token holdings and their correlation with market volatility?
Can you elaborate on how the recent cost reduction initiatives will impact the overall financial outlook for BNB Plus Corp. (Applied DNA Sciences Inc. BNBX) in the coming fiscal year?
What future projects or developments can investors expect from LineaRx that would enhance its market position and revenue generation potential post-2026?
**MWN-AI FAQ is based on asking OpenAI questions about Applied DNA Sciences Inc. (NASDAQ: BNBX).
NASDAQ: BNBX
BNBX Trading
3.81% G/L:
$0.7785 Last:
2,792 Volume:
$0.75 Open:
